Methods for predicting relative efficacy of a beta blocker therapy based on a B1-adrenergic receptor polymorphism
US7449292B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2004 |
| Grant date | Nov 11, 2008 |
| Priority date | — |
| Expiry date | Feb 25, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of β1-adrenergic receptor are provided. The Gly389 β1-adrenergic receptor variants are not as responsive to treatment β blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping β1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the β1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.